[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 2, 1983

Chronic Myelogenous Leukemia: Development of Blast Crisis With Both Lymphoid and Myeloid Features

Author Affiliations

From the Departments of Medicine (Drs Skubitz, Craddock, Weisdorf, Flynn, and Hammerschmidt) and Laboratory Medicine and Pathology (Drs LeBien, Kersey, and Brunning and Ms Parkin), University of Minnesota Medical School, Minneapolis; and the Department of Medicine, Duke University Medical School, Durham, NC (Dr Niedel). Dr Craddock is now with the Department of Medicine, University of Kentucky, Lexington.

JAMA. 1983;250(21):2957-2960. doi:10.1001/jama.1983.03340210055025

A 50-year-old man had chronic myelogenous leukemia and entered a blast crisis that was both morphologically and histochemically lymphoid. The blasts contained terminal deoxyribonucleotidyl transferase and expressed lymphoblastic leukemia-associated antigen. He rapidly entered remission with vincristine sulfate and prednisone therapy. Nevertheless, his blasts displayed a marker generally considered unique to myeloid cells: they selectively bound the granulocyte chemotaxin N-formyl-Met-Leu-Phe. In addition, some cells contained granules resembling those of basophils or mast cells. Such mixed myeloid-lymphoid features in chronic myelogenous leukemia blast cells may reflect malignant transformation of a stem cell capable of both myeloid and lymphoid differentiation, or they may reflect the dedifferentiation as a feature of malignant change.

(JAMA 1983;250:2957-2960)